ME
ALXN

McIlrath & Eck’s Alexion Pharmaceuticals ALXN Stock Holding History

McIlrath & Eck’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-106
Closed -$12K – 722
2020
Q3 		$12K Hold
106
– – 0.01% 353
2020
Q2 		$12K Hold
106
– – 0.01% 336
2020
Q1 		$10K Buy
+106
New +$10.4K 0.01% 316

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

McIlrath & Eck's ALXN Position: Q4 2020 in Review

McIlrath & Eck sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 106 shares — an estimated $12K sold.

McIlrath & Eck first reported a position in ALXN in Q1 2020 and held it in 3 quarters. The position peaked at $12K in Q3 2020. 827 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

  • McIlrath & Eck reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • McIlrath & Eck sold 106 Alexion Pharmaceuticals shares in Q4 2020, an estimated $12K.
  • McIlrath & Eck first reported a position in Alexion Pharmaceuticals in Q1 2020 and held it in 3 quarters.
  • McIlrath & Eck's Alexion Pharmaceuticals position peaked at $12K in Q3 2020.
  • 827 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on McIlrath & Eck's 13F filing for Q4 2020, filed 5 Feb 2021.